EPS: As of FY2025 Q2, the actual value is USD -0.32.EBIT: As of FY2025 Q2, the actual value is USD -6.22 M, beating the estimate of USD -8.031 M.<h3>Segment Revenue</h3>Annovis Bio, Inc. has not generated any revenue since commencing significant operations in 2008.<h3>Operational Metrics</h3><ul><li>Net Loss: The net loss for the three months ended June 30, 2025 was $6.2 million, compared to $5.0 million for the same period in 2024, representing an increase of $1.2 million.</li><li>Operating Loss: The operating loss for the six months ended June 30, 2025 was $12.6 million, compared to $15.6 million for the same period in 2024, showing a decrease of $3.0 million.</li><li>Research and Development Expenses: For the three months ended June 30, 2025, research and development expenses were $5.2 million, compared to $5.8 million for the same period in 2024, a decrease of $0.6 million.</li><li>General and Administrative Expenses: For the three months ended June 30, 2025, general and administrative expenses were $1.1 million, compared to $2.0 million for the same period in 2024, a decrease of $0.9 million.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: Cash used in operating activities was $13.2 million for the six months ended June 30, 2025, compared to $10.4 million for the same period in 2024.</li><li>Financing Activities: Cash provided by financing activities for the six months ended June 30, 2025 was $19.8 million, primarily from the ThinkEquity offering and ATM facility.</li></ul><h3>Unique Metrics</h3><ul><li>Warrant Liability: The warrant liability decreased from $737,000 as of December 31, 2024, to $319,000 as of June 30, 2025.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: Annovis Bio plans to continue the development of its lead product candidate, buntanetap, with ongoing Phase 3 trials for Alzheimer’s disease and Parkinson’s disease. The company aims to file New Drug Applications for short-term and long-term efficacy based on trial results.</li><li>Funding Requirements: The company anticipates needing to raise substantial additional capital to complete the development and commercialization of its product candidates through various financing alternatives.</li></ul>

Annovis Bio | 10-Q: FY2025 Q2 EPS: USD -0.32